The EED Knockout NCI-H1975 Polyclonal Cells product consists of a CRISPR/Cas9-edited polyclonal population of NCI-H1975 non-small cell lung cancer (NSCLC) cells with targeted disruption of the EED gene. This polyclonal knockout format provides a heterogeneous, functionally EED-deficient model that avoids clonal artifacts, enabling robust analysis of Polycomb Repressive Complex 2 (PRC2) function. The pool retains the key genetic background of the parental line while lacking intact EED, allowing investigation of EED-dependent pathways.
The NCI-H1975 cell line is a human lung adenocarcinoma model with activating EGFR L858R/T790M mutations, widely used to study EGFR-mutant NSCLC and therapy resistance. These epithelial cells serve as a physiologically relevant host for probing epigenetic contributions to oncogenic signaling. Their defined genetic landscape, including mutant EGFR and wild-type KRAS, makes them ideal for examining crosstalk between the EGFR pathway and repressive chromatin complexes like PRC2.
EED is a core component of PRC2, also comprising EZH2, SUZ12, and RBBP4/7. EED binds H3K27me3 and allosterically activates EZH2, propagating histone methylation and gene repression. Upstream regulators such as HOTAIR lncRNA, AKT, and E2F factors influence PRC2 recruitment, while downstream targets include tumor suppressors CDKN2A and CDKN1A and HOX clusters. EED interacts with SUZ12, AEBP2, and JARID2 to anchor the complex to chromatin. Its disruption abrogates the H3K27me3 silencing loop, leading to reactivation of key regulatory genes.
In NCI-H1975, EED knockout dismantles PRC2-mediated repression, reducing H3K27me3 and derepressing tumor suppressors that may counteract EGFR-driven proliferation. This model enables dissection of how epigenetic silencing sustains the malignant phenotype and synergy with EGFR inhibitors. It is especially valuable for studying PRC2 dysregulation in NSCLC and evaluating EED as a therapeutic target, as EED loss provides a precise tool to interrogate chromatin dynamics without affecting H3K27me3 initiation.
Applications include Western blot and ChIP-qPCR for H3K27me3 profiling, RT-qPCR for target gene expression, proliferation and drug sensitivity assays, and RNA-seq for transcriptome-wide effects. The polyclonal knockout format suits high-throughput screens and avoids clone-specific biases. This model is a versatile tool for epigenetic regulation studies, drug resistance research, and functional genomics in lung cancer. For further details, please contact Ascent Research.
